PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
about
Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Release of Doxorubicin by a Folate-Grafted, Chitosan-Coated Magnetic NanoparticleAndrogen deprivation therapy has no effect on Pim-1 expression in a mouse model of prostate cancer.Therapeutic Approaches Targeting MYC-Driven Prostate CancerPIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.In vivo Reprogramming of Cancer Metabolism by MYC.Non-invasive (89)Zr-Transferrin PET Shows Improved Tumor Targeting Compared to (18)F-FDG PET in MYC-overexpressing Human Triple Negative Breast Cancer.PIM1: a promising target in patients with triple-negative breast cancer.Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.MCL-1 is a prognostic indicator and drug target in breast cancer.AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.PIM1 mediates epithelial-mesenchymal transition by targeting Smads and c-Myc in the nucleus and potentiates clear-cell renal-cell carcinoma oncogenesis.Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer.Pim1 supports human colorectal cancer growth during glucose deprivation by enhancing the Warburg effect.Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancerPIM Kinase as an Executional Target in CancerIn vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cellsDownregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer
P2860
Q33591876-42E8B417-D2F3-4158-BB1C-B8D20B7899C0Q33611961-163E863A-114D-47C6-AC19-DAC460A461AEQ33751248-4EAC27C0-4A9E-4C90-B888-F069A9A92DB7Q37676253-42AE7544-AA9A-4133-B9B6-B7B33037DB68Q37686796-5CA64857-71A4-471F-93C1-815A54C921EEQ37746816-E9E0CFCE-9A2A-4114-B25B-FEB27FE57C9DQ38605112-8F9FB960-7FAE-44B7-B7E4-D9DA72B72E91Q39443294-9715D670-CD87-4481-9D08-60D0134B771DQ41708939-5226F0BC-4545-4B85-989C-A1073C98B7A3Q48231466-2FC8F3F4-AEDC-48DB-92E5-40593E6C1C61Q50019745-AC0C19D1-5918-4D95-A0EA-E191329447CEQ52344482-F3D5B3F6-98B1-4AB5-BBB1-C012210665DEQ52689146-7149F219-37E5-4683-9BDB-150E0EDAC10CQ52726773-F00E3FD7-4C6E-4047-AB00-7E4D7258CE5AQ54796100-27562F11-2155-43CF-9798-9C6CA539591FQ54982371-F4B0C60C-4D9E-4AF0-9E73-EEE41BA7E992Q54999476-583D3F06-F2FD-4E3F-B6DB-4E70D0646FF5Q57817294-5E976ED8-5C61-48E8-B9E7-F93907E96C0AQ58128483-4B5F2452-BC2C-498C-8DC0-B2656EB83A41Q58695321-CE7A3FCB-D0F7-4E6F-A630-03755B0B7BF0Q58699999-56179023-A5EF-4770-856B-F52548842B40Q59126036-C3E9C162-D232-4C4E-A2E0-4980EB49BD94
P2860
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PIM1 kinase regulates cell dea ...... triple-negative breast cancer.
@en
type
label
PIM1 kinase regulates cell dea ...... triple-negative breast cancer.
@en
prefLabel
PIM1 kinase regulates cell dea ...... triple-negative breast cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
PIM1 kinase regulates cell dea ...... triple-negative breast cancer
@en
P2093
Anna Perdrix-Rosell
Darren A Plumb
Elodie Noël
Erika Francesch-Domenech
Fara Brasó-Maristany
Farzana Noor
Gianmaria Liccardi
Jelmar Quist
Johnathan Watkins
Kristen McEachern
P2507
P2860
P2888
P304
P356
10.1038/NM.4198
P407
P50
P577
2016-10-24T00:00:00Z